

Hydroxycarbamide (hydroxyurea)

Essential medicine status

General description

Hydroxyurea (also known as hydroxycarbamide) is used in the management of sickle cell disease, and in treatment protocols for chronic myeloproliferative disorders.

INN

Hydroxycarbamide

ATC codes

[L01XX05](#)

Medicine type

Chemical agent

EML status history

First added in 2009 ([TRS 958](#)) for [Chronic myeloid leukaemia, not elsewhere classified](#)

Added in 2009 ([TRS 958](#)) for [Squamous cell carcinoma of oropharynx](#)

Added in 2011 ([TRS 965](#)) for [Other specified sickle cell disorders or other haemoglobinopathies](#)

Removed in 2015 ([TRS 994](#)) for [Squamous cell carcinoma of oropharynx](#)

Wikipedia

[Hydroxycarbamide \(hydroxyurea\)](#)

DrugBank

[Hydroxycarbamide \(Hydroxyurea\)](#)

Recommendations

Section

Cytotoxic medicines

- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg
- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

Indications

[Chronic myeloid leukaemia, not elsewhere classified](#) [Squamous cell carcinoma of oropharynx](#)

Section

Medicines for haemoglobinopathies

- Oral > Solid > dosage form: 200 mg; 500 mg; 1 g; 100 mg

Indications

[Other specified sickle cell disorders or other haemoglobinopathies](#)